vs
Side-by-side financial comparison of TPG Mortgage Investment Trust, Inc. (MITT) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
TPG Mortgage Investment Trust, Inc. is the larger business by last-quarter revenue ($20.4M vs $13.7M, roughly 1.5× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 65.0%, a 10.7% gap on every dollar of revenue.
TPG Mortgage Investment Trust, Inc. is a real estate investment trust managed by global alternative asset firm TPG. It primarily invests in residential and commercial mortgage-backed securities, performing and non-performing mortgage loans, and other credit-linked real estate assets, with its core market being the United States. It generates returns via net interest income from holdings and strategic asset disposition gains.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
MITT vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.4M | $13.7M |
| Net Profit | $13.3M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | 67.1% | -86.5% |
| Net Margin | 65.0% | 75.7% |
| Revenue YoY | 17.7% | — |
| Net Profit YoY | -7.0% | 179.1% |
| EPS (diluted) | $0.27 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.4M | $13.7M | ||
| Q3 25 | $19.5M | $19.1M | ||
| Q2 25 | $17.8M | $8.1M | ||
| Q1 25 | $18.8M | $2.9M | ||
| Q4 24 | $17.4M | — | ||
| Q3 24 | $14.9M | — | ||
| Q2 24 | $16.4M | — | ||
| Q1 24 | $17.2M | — |
| Q4 25 | $13.3M | $10.4M | ||
| Q3 25 | $20.0M | $-16.3M | ||
| Q2 25 | $3.9M | $-15.8M | ||
| Q1 25 | $11.5M | $-13.3M | ||
| Q4 24 | $14.3M | — | ||
| Q3 24 | $16.6M | — | ||
| Q2 24 | $3.9M | — | ||
| Q1 24 | $20.9M | — |
| Q4 25 | 67.1% | -86.5% | ||
| Q3 25 | — | -10.1% | ||
| Q2 25 | 20.9% | -177.7% | ||
| Q1 25 | 54.6% | -472.7% | ||
| Q4 24 | 76.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 18.4% | — | ||
| Q1 24 | — | — |
| Q4 25 | 65.0% | 75.7% | ||
| Q3 25 | 102.5% | -85.4% | ||
| Q2 25 | 22.2% | -196.0% | ||
| Q1 25 | 60.9% | -452.7% | ||
| Q4 24 | 82.2% | — | ||
| Q3 24 | 111.3% | — | ||
| Q2 24 | 24.0% | — | ||
| Q1 24 | 121.6% | — |
| Q4 25 | $0.27 | $-3.74 | ||
| Q3 25 | $0.47 | $-0.11 | ||
| Q2 25 | $-0.05 | $-0.16 | ||
| Q1 25 | $0.21 | $-0.18 | ||
| Q4 24 | $0.30 | — | ||
| Q3 24 | $0.40 | — | ||
| Q2 24 | $-0.02 | — | ||
| Q1 24 | $0.55 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $57.8M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $560.7M | $35.3M |
| Total Assets | $8.7B | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $57.8M | $137.5M | ||
| Q3 25 | $59.0M | $103.8M | ||
| Q2 25 | $88.7M | $121.6M | ||
| Q1 25 | $115.5M | $89.1M | ||
| Q4 24 | $118.7M | — | ||
| Q3 24 | $102.5M | — | ||
| Q2 24 | $120.9M | — | ||
| Q1 24 | $100.3M | — |
| Q4 25 | $560.7M | $35.3M | ||
| Q3 25 | $559.8M | $-8.1M | ||
| Q2 25 | $536.4M | $7.1M | ||
| Q1 25 | $543.9M | $10.7M | ||
| Q4 24 | $543.4M | — | ||
| Q3 24 | $540.1M | — | ||
| Q2 24 | $533.5M | — | ||
| Q1 24 | $539.6M | — |
| Q4 25 | $8.7B | $154.7M | ||
| Q3 25 | $9.0B | $133.7M | ||
| Q2 25 | $7.5B | $133.8M | ||
| Q1 25 | $7.3B | $103.7M | ||
| Q4 24 | $6.9B | — | ||
| Q3 24 | $7.0B | — | ||
| Q2 24 | $7.1B | — | ||
| Q1 24 | $6.4B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $59.6M | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | 4.48× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $59.6M | $-2.0M | ||
| Q3 25 | $17.4M | $-17.5M | ||
| Q2 25 | $11.5M | $-14.5M | ||
| Q1 25 | $12.0M | $29.0M | ||
| Q4 24 | $55.8M | — | ||
| Q3 24 | $14.5M | — | ||
| Q2 24 | $13.7M | — | ||
| Q1 24 | $12.0M | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 4.48× | -0.19× | ||
| Q3 25 | 0.87× | — | ||
| Q2 25 | 2.92× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 3.91× | — | ||
| Q3 24 | 0.87× | — | ||
| Q2 24 | 3.50× | — | ||
| Q1 24 | 0.57× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
